{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T02:59:13Z","timestamp":1785121153163,"version":"3.55.0"},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BTT"],"DOI":"10.2147\/btt.s581444","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T02:05:14Z","timestamp":1785117914000},"page":"1-11","source":"Crossref","is-referenced-by-count":0,"title":["Safety Profile of Tozorakimab (an Anti-IL-33 Monoclonal Antibody): Data from the FRONTIER Phase 2 Program"],"prefix":"10.2147","volume":"Volume 20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1344-2721","authenticated-orcid":true,"given":"Rajesh","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Gorseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Moate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Hofherr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Kell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2131-8013","authenticated-orcid":true,"given":"Gabriela","family":"Luporini Saraiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitesh","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Psallidas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7]]},"container-title":["Biologics: Targets and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/article\/download\/117698","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/article\/download\/117698","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T02:05:14Z","timestamp":1785117914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/safety-profile-of-tozorakimab-an-anti-il-33-monoclonal-antibody-data-f-peer-reviewed-fulltext-article-BTT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/btt.s581444","relation":{},"ISSN":["1177-5491"],"issn-type":[{"value":"1177-5491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}